Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.

Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis

Open access
McMillan, Jacqueline M, Mele, Bria S, Hogan, David B, Leung, Alexander A · 2018 · BMJ Open Diabetes Research & Care

Abstract

Background: The association between diabetes mellitus (DM) treatment and dementia is not well understood. Objective: To investigate the association between treatment of diabetes, hypoglycemia, and dementia risk. Research design and methods: We performed a systematic review and meta-analysis of pharmacological treatment of diabetes and incident or progressive cognitive impairment. We searched Ovid MEDLINE, Embase, Cochrane Central Registry of Controlled Trials, and PsychINFO from inception to 18 October 2017. We included cross-sectional, case–control, cohort, and randomized controlled studies. The study was registered with PROSPERO (ID CRD42017077953). Results: We included 37 studies into our systematic review and 13 into our meta-analysis. Ten studies investigated any antidiabetic treatment compared with no treatment or as add-on therapy to prior care. Treatment with an antidiabetic agent, in general, was not associated with incident dementia (risk ratio (RR) 1.01; 95% CI 0.93 to 1.10). However, we found differential effects across drug classes, with a signal of harm associated with insulin therapy (RR 1.21; 95% CI 1.06 to 1.39), but potentially protective effects with thiazolidinedione exposure (RR 0.71; 95% CI 0.55 to 0.93). Severe hypoglycemic episodes were associated with a nearly twofold increased likelihood of incident dementia (RR 1.77; 95% CI 1.35 to 2.33). Most studies did not account for DM duration or severity. Conclusions and limitations: The association between treatment for diabetes and dementia is differential according to drug class, which is potentially mediated by hypoglycemic risk. Not accounting for DM duration and/or severity is a major limitation in the available evidence base.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjdrc-2018-000563

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Relative risk of developing dementia with intensive versus non-intensive antidiabetic treatment. RR, risk ratio; TZD, thiazolidinedione.
Figure 1 Relative risk of developing dementia with intensive versus non-intensive antidiabetic treatment. RR, risk ratio; TZD, thiazolidinedione.CC BY-NC · PubMed Central
Figure 2 Relative risk of developing dementia by treatment type. RR, risk ratio; TZD, thiazolidinedione.
Figure 2 Relative risk of developing dementia by treatment type. RR, risk ratio; TZD, thiazolidinedione.CC BY-NC · PubMed Central
Figure 3 Relative risk of developing dementia based on to the occurrence of one or more hypoglycemic events. RR, risk ratio.
Figure 3 Relative risk of developing dementia based on to the occurrence of one or more hypoglycemic events. RR, risk ratio.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Research works printed but not linked: 4

  1. Hsiao, 2014, Risk for Alzheimer's disease in type 2 diabetic patients treated with metformin, Diabetes, 63
  2. Naharci, 2016, Association of metformin therapy with the risk of dementia in older adults with type 2 diabetes mellitus, European Geriatric Medicine, 7, S62
  3. Zullo, 2017, The effect of dipeptidyl peptidase-4 inhibitors versus sulfonylureas on mental status, cognition, and physical functioning in older nursing home residents, J Am Geriatr Soc, 65, S220
  4. KH, 2017, Severe hypoglycemia and risk of dementia in person with diabetes mellitus, Journal of Diabetes Investigation, 8

Cited by

See all 91

Metadata

Authors
McMillan, J. M., Mele, B. S., Hogan, D. B., & Leung, A. A.
Affiliations
University of Calgary (CA)
Corresponding author
McMillan, Jacqueline M
Venue
BMJ Open Diabetes Research & Care
Publisher
BMJ
Published
2018-11
Volume
6
Issue
1
Pages
e000563
ISSN
2052-4897 (ISSN-L)
OpenAlex
W2900724835
Cited by
80
References
57
Citations by year
2026: 5 · 2025: 12 · 2024: 6 · 2023: 18 · 2022: 12 · 2021: 9 · 2020: 11 · 2019: 6
FWCI
0.99
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open Diabetes Research & Care (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Government of Alberta
  • Hypertension Canada
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
diabetes mellitus, dementia risk, antidiabetic drugs, insulin therapy, thiazolidinediones, hypoglycemia, cognitive impairment, drug class effect, diabetes duration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis. https://app.cochat.ai/papers/10.1136/bmjdrc-2018-000563
The paper
McMillan, J. M., Mele, B. S., Hogan, D. B., & Leung, A. A. (2018). Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2018-000563

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.